Riskpilot← Back to searchSign inGet full accessNexGenMediQ AB
ABActiveOrg 5594726506Blomvägen 1Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20241-4 employees
Revenue 2025
SEK 355K
+7671% vs 2024
EBITDA margin
-52.9%
-5% vs 2024
Equity ratio
59.2%
Financial strength
Net profit 2025
SEK -189K
-6% vs 2024
| Revenue | SEK 355K | +7671% |
| EBITDA | SEK -188K | -5% |
| Net profit | SEK -189K | -6% |
| Total assets | SEK 455K | +90% |
| Equity | SEK 270K | +122% |
| Employees | — | — |
Legal name
NexGenMediQ AB
Org number
5594726506
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
19 februari 2024
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva försäljning av medicintekniska produkter och hjälpmedel till sjukvården i Skandinavien. Bolaget skall verka som återförsäljare och distributör genom upphandlingar och direktförsäljning av innovativa, professionella varumärken och smarta lösningar från hela världen samt därmed förenlig verksamhet.
Address
Blomvägen 1
Email
micke@nexgenmediq.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2024 | 2025 |
|---|---|---|
| Revenue | 5 | 355 |
| Staff expenses | — | −150 |
| EBITDA | −179 | −188 |
| Depreciation & amort. | — | — |
| EBIT | −179 | −188 |
| Net financials | 0 | −1 |
| Profit before tax | −179 | −189 |
| Tax | — | — |
| Net profit | −179 | −189 |
| Item | 2024 | 2025 |
|---|---|---|
| Total assets | 239 | 455 |
| Equity | 121 | 270 |
| Long-term debt | — | — |
| Short-term debt | 118 | 186 |
| Total debt | 118 | 186 |
EBITDA margin
-52.9%
This company
15.8%
Market median
-435% vs market
20242025
Equity ratio
59.2%
This company
38.2%
Market median
+55% vs market
20242025
Return on equity
-70.0%
This company
18.4%
Market median
-480% vs market
20242025
Net profit margin
-53.1%
This company
8.1%
Market median
-756% vs market
20242025
Asset turnover
0.78×
This company
1.12×
Market median
-30% vs market
20242025
Debt / equity
0.69×
This company
0.62×
Market median
+11% vs market
20242025
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2024 | |
| Deputy Board Member | 2024 | |
| Former (5) | ||
| Deputy Board Member | 2024 – 2024 | |
| Deputy Board Member | 2024 – 2024 | |
| Deputy Board Member | 2024 – 2024 | |
| Deputy Board Member | 2024 – 2024 | |
| Board of Directors | 2024 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NexGenMediQ AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl Philip Anders Franzén | Deputy Board Member | 0 companies |
| Carl Jonas Öman | Deputy Board Member | 0 companies |
| Stina Maria Selldén | Deputy Board Member | 0 companies |
| Emma Tora Karolina Pihl | Board of Directors | 0 companies |
| Erik Alexander Stötsberg | Deputy Board Member | 0 companies |
| Michael Per Viggo Nettelbladt | Deputy Board Member | 0 companies |
| Mikaela Jenni Berglund | Board of Directors | 0 companies |